Activated Carbon For Pharma & Healthcare Market (2026 - 2033)

Activated Carbon For Pharma And Healthcare Market Summary

The global activated carbon for pharma and healthcare market size was valued at USD 479.7 million in 2025 and is projected to grow from USD 511.4 million in 2026 to USD 741.9 million by 2033, growing at a CAGR of 5.5% from 2026 to 2033. Asia Pacific dominated the market, accounting for the largest global share of 48.6% in 2025. Its exceptional purification and adsorption properties propel the rising demand for activated carbon in the pharmaceutical and healthcare sectors. 

Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases

To learn more about this report, Download Free Sample Report

It plays a crucial role in applications such as air and water purification in hospitals and pharmaceutical manufacturing, as it eliminates impurities and decolorants from medications. The growing demand for activated carbon in the healthcare sector is closely linked to the high incidence of hospital-acquired infections (HAIs) in the U.S. Each year, around 1.7 million inpatients-roughly one in every 20-contract an HAI, with 5%-10% of hospitalized patients affected and nearly 100,000 resulting deaths. These alarming figures surpass the incidence and mortality rates of many other reportable diseases, highlighting the urgent need for advanced air and water purification solutions  Activated carbon, known for its effective filtration and adsorption capabilities, is increasingly being adopted to help maintain sterile environments and reduce the risk of infection in medical facilities.

To learn more about this report, Download Free Sample Report

Furthermore, their demand is driven by their essential role in decolorization and purification. Its highly porous structure, enhanced through thermal activation, allows for efficient impurities, pigments, and dyes adsorption. This improves product quality, safety, and appearance. Activated carbon is widely used during production to trap unwanted substances, ensuring cleaner, more effective drugs. The industry's increasing R&D investments further fuel the need for high-performance purification solutions such as activated carbon. These factors fuel the demand for activated carbon for the pharma & healthcare industry.

Market Dynamics

The Activated Carbon for Pharma & Healthcare market is experiencing steady growth driven by increasing demand for durable, high-performance protective coatings across industries such as automotive, construction, industrial equipment, wood finishing, and aerospace. Activated Carbon for Pharma & Healthcare are widely valued for their excellent abrasion resistance, chemical resistance, weatherability, UV stability, and aesthetic finish. Growing infrastructure development, rising automotive production, and increasing investments in industrial manufacturing are supporting market expansion. In addition, the shift toward environmentally friendly coating technologies, including waterborne and low-VOC formulations, is creating new growth opportunities for the Activated Carbon for Pharma & Healthcare market.

Analyst Perspective

The Activated Carbon for Pharma & Healthcare market is expected to witness steady growth owing to increasing pharmaceutical manufacturing, expanding biologics production, and growing emphasis on high-purity processing. Rising regulatory requirements for impurity control, solvent purification, and pharmaceutical water treatment are accelerating the adoption of pharmaceutical-grade activated carbon across API manufacturing and biopharmaceutical facilities. Additionally, increasing utilization in medical therapies such as hemoperfusion and poisoning treatment, coupled with investments in healthcare infrastructure and CDMO expansion, is expected to support long-term market growth. Manufacturers focusing on high-purity grades, regulatory compliance, and customized adsorption performance are likely to strengthen their competitive position across the pharmaceutical and healthcare 

Form Insights

Powdered segment dominated the form segment at a revenue share of 56.0% in 2025. Powdered Activated Carbon (PAC) has proven effective in reducing pharmaceutical compounds in wastewater, with a 63-84% reduction in discharged carbamazepine and diclofenac at dosing levels of 10-25 mg/L. PAC is an essential tool for controlling pharmaceutical contaminants in municipal wastewater treatment. It also enhances sludge quality, increasing the dry weight by +1% while limiting the sludge production increase to 7-9%, contributing to more efficient waste management

The granular activated carbon segment is expected to grow at the fastest CAGR of 5.9% over the forecast period. The granular form is increasingly preferred by pharma and healthcare companies owing to its key properties, such as superior absorption, ease of handling and storage, and regeneration capacity. The ability of granular activated carbon to withstand the repeated cycles of filtration primarily drives the growing adoption. Increasing collaborations and supply contracts among market participants also contribute to the growth experience of this segment. In 2024, Arq, Inc., one of the key manufacturers of Granular Activated Carbon (GAC), announced that it secured multiple supply contracts for its GAC product, mainly designed for processes associated with raw material purification.

Application Insights

API Production segment accounted for the largest revenue share of 60.2% in 2025. During API production, which is the key component of medicines, responsible for their therapeutic effects, activated carbon helps remove impurities, decolorization, pH adjustment, stability, prevent contamination, and enhance product quality. The pharmaceutical industry is one of the most rapidly evolving sectors worldwide, with active pharmaceutical ingredients playing a central role.

The finished drug production segment is expected to grow significantly over the forecast period. Activated carbon plays a key role in pharmaceutical wastewater treatment, removing residual drugs and contaminants to ensure environmental compliance after drug production.

To learn more about this report, Download Free Sample Report

Regional Insights

Asia Pacific accounted for 48.6% of the activated carbon for pharma & healthcare market revenue in 2025, making it the largest regional market. The demand is rising due to rapid industrialization and urbanization. Increased pharmaceutical production in Asian countries further drives the need for efficient purification. Leading companies such as Takeda Pharmaceutical Company Limited, Sun Pharmaceutical Industries Ltd., and Cipla contribute significantly to this demand, using activated carbon in various drug manufacturing and filtration processes.

To learn more about this report, Download Free Sample Report

China Activated Carbon For Pharma & Healthcare Market Trends

China held the highest market revenue share in Asia Pacific in 2025. China’s expanding pharmaceutical and healthcare sectors fuel demand for activated carbon, essential for purifying APIs and intermediates in drug production. Since 2021, the industry has grown at an average annual rate of 9.3%, driven by the 14th Five-Year Plan, according to the Ministry of Industry and Information Technology. Strict environmental regulations on pharmaceutical emissions and waste management have increased the use of activated carbon for air and water purification. In addition, activated carbon tablets and capsules are widely used in hospitals and pharmacies to treat poisoning, indigestion, and flatulence.

North America Activated Carbon For Pharma & Healthcare Market Trends

The activated carbon for pharma & healthcare market in North America held a substantial market share in 2025. The growing pharmaceutical manufacturing industries and advancements in cleaner healthcare sectors are driving the market demand. Furthermore, it is used to treat over-the-counter stomach issues, which are continuously increasing according to the American Gastroenterological Association (AGA). In 2022, it was reported that 60-70 million Americans were suffering from gastrointestinal diseases . In addition, North America accounted for 49.1% of global pharmaceutical sales  in 2021, indicating the region’s dominant position in the global pharma market, accelerating the demand for activated carbon.

The U.S. activated carbon for pharma & healthcare market led the North American market, accounting for the largest revenue share in 2025. The growing demand is driven by several key factors, such as increasing regulatory pressures from agencies such as the FDA, along with stricter environmental guidelines, which are pushing companies to adopt higher standards of purity and filtration in drug manufacturing. Activated carbon meets these standards by removing impurities from active pharmaceutical ingredients and intermediates. Its medical applications, particularly in treating drug overdoses, have become increasingly vital, highlighted by the 105,007 overdose deaths reported in 2023 . Rising environmental and health awareness also encourages cleaner and more sustainable production practices in the healthcare sector.

Europe Activated Carbon For Pharma & Healthcare Market Trends

The activated carbon for pharma & healthcare market in Europe held a substantial market share in 2025. The increasing demand is largely driven by its expanding use across various industries, including pharmaceuticals. In 2022, the pharmaceutical sector invested over USD 53.5 million in R&D  in Europe. Furthermore, the growing digestive disorder in the region is a major driver for activated carbon, as it helps manage certain symptoms. According to a report from United European Gastroenterology (UEG), in 2023, over 332 million people are estimated to be living with a digestive disorder in the region. 

Key Activated Carbon For Pharma & Healthcare Company Insights

Some major companies in the activated carbon for pharma & healthcare industry are Osaka Gas Chemicals Co., Ltd., Calgon Carbon Corporation, JACOBI CARBONS GROUP, and Cabot Corporation. These companies focus on innovating purification technologies, ensuring compliance with stringent regulatory standards, and expanding product applications. They focus on high-quality, efficient solutions for pharmaceutical manufacturing, wastewater treatment, and medical uses such as poisoning treatments. Strong R&D investments and strategic partnerships with leading pharma companies also help sustain growth.

• Osaka Gas Chemicals Co., Ltd. produces materials such as activated carbon, carbon fiber, fine chemicals, and wood preservatives. The company serves various industries, including pharmaceuticals, electronics, and environmental sectors, and it focuses on innovation and sustainability in its product offerings and operations.

• Calgon Carbon Corporation manufactures coal, wood, and coconut-based activated carbon products in granular, powdered, pelletized, and cloth forms.

Key Activated Carbon For Pharma & Healthcare Companies

The following key companies have been profiled for this study on the activated carbon for pharma & healthcare market.

• Jacobi Group

• Chemviron (a Kuraray Company)

• Haycarb PLC

• Boyce Carbon

• Southern Carbon Pvt. Ltd.

• Suneeta Carbons

• Calgon Carbon Corporation

• Karbonous Inc.

• Norit

• Donau Carbon GmbH

Recent Developments

• In February 2025, JACOBI CARBONS GROUP announced that a 15-20% price increase would be implemented from April 2025 on all coconut shell-based activated carbons. A recent surge in raw material costs necessitated the adjustment.

• In December 2024, CPL/Puragen Activated Carbons, ADBA members, won the Energy Innovation award at the MRW National Recycling Awards 2024 for their breakthrough in reactivating high-sulfur spent carbon from the biogas sector-a previously untreatable waste.

Global Activated Carbon For Pharma & Healthcare Market Report Segmentation

This report forecasts volume & revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global activated carbon for pharma & healthcare market report based on form, application, and region:

To learn more about this report, Download Free Sample Report

• Form Outlook (Volume, Kilotons; Revenue, USD Million, 2021 - 2033)

  • Powdered       

  • Granular

  • Other Form

• Application Outlook (Volume, Kilotons; Revenue, USD Million, 2021 - 2033)

  • API Production

  • Finished Drug Production

  • Others

• Regional Outlook (Volume, Kilotons; Revenue, USD Million, 2021 - 2033)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • Germany

    • UK

    • France

    • Italy

    • Spain

  • Asia Pacific

    • China

    • India

    • Japan

    • South Korea

    • Australia

  • Latin America

    • Brazil

    • Argentina

  • Middle East and Africa (MEA)

    • South Africa

    • Saudi Arabia

Research Methodology

The activated carbon for pharma & healthcare market figures in this report are based on a proven research process that combines executive interviews with secondary research from proprietary databases, company filings, and recognized regulatory and institutional sources. Market size is built through value-chain sizing - reconciling supply-side and demand-side estimates - and triangulated with bottom-up and top-down approaches. Every estimate passes multiple levels of expert validation before publication, with each activated carbon for pharma & healthcare segment quantified using the revenue-capture definitions in the table below.

Delivered Customizations

This report has been delivered with the following In-depth customizations